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Abstract
Background: Cardiovascular disease is the leading cause of morbidity and
mortality in the developed world. To reduce this burden of disease, a German
sickness fund (‘Siemens-Betriebskrankenkasse’, SBK) initiated the prevention
programme ‘KardioPro’ including primary (risk factor reduction) and secondary
(screening) prevention and guideline-based treatment. The aim of this study was to
assess the effectiveness of ‘KardioPro’ as it is implemented in the real world.
Methods: The study is based on sickness fund routine data. The control group was
selected from non-participants via propensity score matching. Study analysis was
based on time-to-event analysis via Cox proportional hazards regression with the
endpoint ‘all-cause mortality, acute myocardial infarction (MI) and ischemic stroke
(1)’, ‘all-cause mortality (2)’ and ‘non-fatal acute MI and ischemic stroke (3)’.
Results: A total of 26,202 insurants were included, 13,101 participants and 13,101
control subjects. ‘KardioPro’ enrolment was associated with risk reductions of
23.5% (95% confidence interval (CI) 13.0–32.7%) (1), 41.7% (95% CI 30.2–51.2%)
(2) and 3.5% (hazard ratio 0.965, 95% CI 0.811–1.148) (3). This corresponds to an
absolute risk reduction of 0.29% (1), 0.31% (2) and 0.03% (3) per year.
Conclusion: The prevention programme initiated by a German statutory sickness
fund appears to be effective with regard to all-cause mortality. The non-significant
reduction in non-fatal events might result from a shift from fatal to non-fatal events.
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Introduction
Cardiovascular disease (CVD) accounts for almost half (47%) of all deaths in
Europe [1]. Identifying high-risk subjects and supplying evidence-based treatment
is essential to reduce the burden of CVD within the population [2, 3].
The German health insurance fund SBK (SBK 5 ‘Siemens-
Betriebskrankenkasse’), a large statutory sickness fund with more than one million
insured people, offered their insurants the complex prevention programme
‘KardioPro’ [4]. This programme provides risk-dependent decision algorithms
regarding the diagnosis and treatment of coronary heart disease (CHD). Its
purpose was to improve the reduction in cardiovascular risk factors (primary
prevention) as well as the early detection and treatment of CHD (secondary
prevention). In particular, ‘KardioPro’ aimed to follow evidence-based guidelines
more accurately. A main target group for enrolment in ‘KardioPro’ was insurants
without any previous diagnosis of CHD. Therefore, ‘KardioPro’ differs from
disease management programmes in Germany, which only focus on individuals
suffering from CHD.
Previously, evaluations have shown CHD prevention strategies that were based
on a single measure to be effective in the prevention of CHD and individual risk
assessment for CHD, although to varying degrees [5–11]. For example, non-
invasive imaging can help to reclassify individuals after first risk estimation [3].
Furthermore, knowledge of the individual risk level can modestly increase the
prescribing of drugs by physicians [12], and patients at moderate to high risk who
know their individual risk level have an increased incentive to initiate CVD
prevention [8, 13]. Additionally, risk factor controlling programmes were able to
achieve up to 50% reduction in (CHD) mortality [13, 14]. Improved treatment
achieved a mortality reduction of 40% [15]. Systematic reviews of multifactorial
prevention programmes showed the first hints of effectiveness in individuals with
increased risk or manifest CHD, whereas individuals with no risk did not seem to
benefit from such programmes [16, 17].
However, there is a gap in evaluations of multifactorial prevention programmes
that have been implemented in real-world settings, such as ‘KardioPro’. Currently,
the effectiveness of ‘KardioPro’ is still unknown, as the quality of standard care
has been judged to be of high quality [14], whereas treatment guidelines are often
not followed accurately [18, 19]. The aim of this study was thus to provide
researchers and providers of health care programmes with a real-world assessment
of the effectiveness of ‘KardioPro’ as it is implemented in the service portfolio of
the providing health insurance company.
Methods
Ethics statement
This is a retrospective evaluation of the real-world health care programme
‘KardioPro’, which has been offered to insurants since 2006. ‘KardioPro’ was
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offered as part of the SBK health care basket, which falls within the common
responsibilities of a statutory sickness fund in Germany (see the German Social
Code 1197, 80 SGB X and 11 67, 43 SGB V). All subjects who enrolled in
‘KardioPro’ gave written consent to participation in ‘KardioPro’. According to
German law, an evaluation of ‘KardioPro’ is not required. Originally, no
evaluation of ‘KardioPro’ based on routine data was planned. Apparently, the
evaluation did not have any impact on how subjects were treated or which
subjects were treated. Neither did it affect which data were collected. Furthermore,
the evaluation was commissioned by an independent research group in November
2010. Compliant with German laws, the evaluation was based on anonymized and
de-identified data, and the evaluation concept was approved by the SBK data
protection officer. As the evaluation concept did not affect the treatment of
subjects, and as the data provided for analysis were non-identifiable, no further
approval from an ethics committee was sought. The ethics committee of the State
Chamber of Physicians of Bavaria has confirmed that no ethical approval was
needed.
Study design
We performed a retrospective cohort study based on SBK routine data. The
observation period lasted from 1 January 2007 to 31 December 2011.
Intervention
‘KardioPro’ is a cardiovascular prevention programme supplied by SBK [4]. It
covers complex pathways of diagnosis and treatment which differ according to the
subjects’ risk group. The intervention has been provided exclusively by voluntarily
participating cardiologists, who received additional compensation for ‘KardioPro’
participants from the SBK; ‘KardioPro’ participants themselves were not charged
any additional fees. First, the cardiologists assigned each participant to one of the
following subgroups: subjects with known CHD; subjects without known CHD
but with CHD-related symptoms; and asymptomatic subjects without known
CHD.
Further risk stratification has been based on the PROCAM (Prospective
Cardiovascular Muenster) risk score, which forecasts the 10-year risk of fatal and
non-fatal myocardial infarction (MI) or sudden death at an individual level [20].
Even though the PROCAM score was originally developed for asymptomatic
subjects without known CHD only, it has been applied to all three participant
subgroups. For asymptomatic subjects without known CHD and a low PROCAM
risk (i.e. ,10%), there were no further diagnostics or intervention. For all
remaining participants, the intensity of diagnostics and treatment and the
frequency of follow-up visits depended upon the magnitude of the calculated
PROCAM risk (medium, 10–20%; or high, $20%).
For each of the resulting subgroups, specific medical examinations (e.g. stress
electrocardiogram) and, depending on the results, further diagnostics (e.g.
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coronary calcium score, computerized tomographic angiography or cardiac MRI
(magnetic resonance imaging) study)) were conducted. If suitable, subsequent to
diagnosis, interventions were proposed, such as stenting. Interventions were
conducted at the discretion of the responsible cardiologist. Furthermore, follow-
up examinations were specified, which could vary between 3 months and 5 years.
‘KardioPro’ participants were reminded to keep the corresponding appointments.
Finally, ‘KardioPro’ incorporated the electronic health record and gave
cardiologists the opportunity to conduct novel medical interventions.
‘KardioPro’ ran first in Munich and later also in Coburg, Berlin, Karlsruhe,
Erlangen and North Rhine-Westphalia. All insured people aged 45 years and
above, as well as subjects with CHD, were invited to participate. There were no
further inclusion or exclusion criteria.
Data
All data used were routine data (claims data) from SBK. Besides demographic
characteristics, such as age, sex, type of insurance (e.g. compulsory or voluntary),
reduced earning capacity and postcode, the data also included information
regarding patient-specific resource consumption and morbidity. Morbidity data
were based on information that German sickness funds must provide in order to
receive morbidity-based risk structure compensation (more than 100 binary-
coded disease prevalence variables, ‘hierarchisierte Morbiditätsgruppen’).
Cardiovascular and cerebrovascular events for time-to-event analysis were based
on hospital discharge diagnoses (ICD-10 I21, ICD-10 I22, ICD-10 I63 and ICD-10
I64), which also formed part of the SBK routine data. The information on
coronary artery bypass grafting (CABG) and percutaneous coronary intervention
(PCI) was acquired by screening the claims data for the hospital accounting data
based on the German Classification of Procedures in Medicine (version 2012)
(5360, 5361, 5362, 5363 and 8837). We defined all PCI and CABG not on the day
of a MI as elective interventions.
Definition of the intervention group
In 2006, SBK insurants were provided with information about the novel
prevention programme for the first time. Information was provided exclusively to
insurants aged 45 years and above, as well as to subjects with known CHD of all
ages (the youngest ‘KardioPro’ participant was 39 years old), given that the
insurants were located in one of the regions where ‘KardioPro’ is provided.
Incentives for participation were optimized provision within health services, as
services were provided that are currently not generally reimbursed by statutory
German health insurance (e.g. computerized tomographic angiography, cardiac
MRI). All subjects who enrolled in ‘KardioPro’ from 1 January 2007 to 31
December 2009 were defined as participants, irrespective of whether they actively
participated in the programme. To enable matching, only those subjects were
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included who were insured with SBK for the whole calendar year before
enrolment.
Building the control group
The control group was built via propensity score matching [21, 22]. The
propensity score was built using three logistic regression models (for the years of
enrolment 2007, 2008 and 2009) based on the characteristics of the year before
enrolment, as most variables referred to a whole calendar year. Each model was
built separately in order to account for the changing explanatory power of
variables for the different years of enrolment, which is likely to be present in open
populations [23, 24]. The independent variables were detected via stepwise
variable selection out of more than 140 variables including demographic data,
comorbidities and consumption of resources. The selected independent variables
can be found in the supplementary material (Table S1). We used an approximate
nearest neighbour 1:1 matching algorithm without replacement. It was conducted
based on a published SAS macro [25].
Potential control subjects were all those who so far had never been enrolled in
‘KardioPro’ at the point of matching. Thus, those who enrolled in ‘KardioPro’ in
later years were not excluded. Inclusion criteria for potential control subjects were
being aged 39 years and above, being located in a region where participation in
‘KardioPro’ was possible and being insured for the whole calendar year of
matching.
To check the comparability of the groups with respect to observed variables, the
distribution of covariates was compared using standardized differences (one test
per variable times each matching year) [21]. A matched pair was excluded from
the analysis if the participant had an event (MI or stroke) or underwent a
cardiovascular intervention (PCI or CABG) on the day of enrolment, as it could
be assumed that the enrolment was not independent of having an event. Likewise,
we also excluded matched pairs if the control subject had an event or
cardiovascular intervention on exactly the same day as their partner’s enrolment.
Additionally, matching pairs were excluded if one of them left the SBK on the day
of enrolment.
Statistical analysis
All statistical analyses were performed using SAS software (version 9.2, SAS
Institute Inc., Cary, NC, USA).
Time-to-event analysis
Primary analysis was based on the combined endpoint of ‘all-cause mortality,
acute MI and ischemic stroke’. The rationale for applying this combined
endpoint, in particular for including all-cause mortality, was because fatal
cardiovascular events that occur outside the hospital setting are not generally
registered within the sickness funds data. However, health insurance companies in
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Germany are informed about the death of insured subjects. Furthermore, a
reduction in cardiovascular mortality via ‘KardioPro’ was expected as a result of
the prevention of cardiovascular events. Therefore, we included acute MI and
ischemic stroke in the combined endpoint as these are major severe events that are
expected to be validly documented in the health insurance data.
Secondary analyses referred to the endpoints ‘all-cause mortality’ and ‘non-fatal
acute MI or non-fatal ischemic stroke’, whereas an event was counted as fatal if
death occurred on the same day. The primary and secondary endpoints were
defined explicitly prior to data analysis (study protocol). Censoring occurred at
the end of the follow-up period, when individuals left the SBK and when a control
subject became a ‘KardioPro’ participant. For the endpoint ‘non-fatal acute MI or
non-fatal ischemic stroke’, a subject was also censored on death. The observation
time for control subjects started when their matched partners enrolled.
Kaplan–Meier curves with point-wise 95% confidence bands were used to
illustrate the results. Cox proportional hazards regression models were applied to
evaluate the effect of ‘KardioPro’. The proportional hazard assumption was tested
by Schoenfeld residuals and was given for each model. As matched pairs were
analysed, a paired version of the Cox regression approach was applied [22, 26–30].
Reported confidence intervals are based on the Wald test.
We also reported absolute risk reductions, which were estimated based on the
event rates (i.e. number of events divided by the number of observation years). To
derive the absolute risk reduction per year, these rates were transformed to annual
probabilities, and the difference between the intervention and control groups was
calculated.
Further analyses
The influence of ‘KardioPro’ on elective PCI and CABG was tested via McNemar
tests. This was done by comparing the number of matched pairs in which the
‘KardioPro’ participant did not but the control subject did receive treatment with
the number of pairs in which the ‘KardioPro’ participant did but the control
subject did not receive treatment [22, 31]. Furthermore, we analysed whether
there were any indicators of ‘KardioPro’ participants being healthier than the
matched control group (‘healthy cohort bias’). To recap, as most of the covariates
that were available for propensity score matching referred to a whole calendar year
only, the calendar year prior to enrolment has been used for matching. Thus, the
disease statuses of the comorbidities for each individual could change from the
year of matching to the year of enrolment, which, in the case of a ‘healthy cohort
bias’, would have yielded imbalanced morbidity between the intervention and
control groups. Thus, such changes in the disease statuses of each individual (no
change in disease status 50, shift to diseased 5+1, shift to non-diseased 521)
were aggregated and compared between the intervention and control groups via
the t-test. Excluded from this analysis were heart diseases and diabetes because
these were explicitly screened for within ‘KardioPro’ and an increase would have
been expected within ‘KardioPro’ participants. Owing to data availability, these
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plausibility checks could only be performed based on changes from 2006 to 2007
and from 2007 to 2008.
Sensitivity analysis
Further Cox regression models, all based on the primary endpoint ‘all-cause
mortality, acute MI and ischemic stroke’, were performed as sensitivity analyses.
First, if one of a matched pair was censored, the other one was also censored at the
same time (simultaneous censoring). Second, the Cox regression was adjusted for
CVD prognostic variables (age, gender, CHD, stroke, hypertension, obesity,
angiopathy and diabetes, with all information gathered in the year of matching).
Third, prospective participants in ‘KardioPro’ were excluded in a second
matching algorithm to avoid early censoring of control subjects. Fourth, a further
control group was built via Mahalanobis distance matching (including subsequent
participants as control subjects, calliper 0.25 standard deviation of the propensity
score; key variables: propensity score, age, sex, CHD, stroke, diabetes and obesity)
[32]. Further sensitivity analyses were conducted in which we changed the
definition of the intervention group and the definition of the endpoints. In the
first of these analyses, ‘KardioPro’ participants and potential control subjects were
excluded prior to conducting propensity score matching if they had at least one
serious health condition in the year prior to the participants’ enrolment into
‘KardioPro’ (the particular illnesses are reported in the online appendix). In the
second of the additional sensitivity analyses, an alternative definition of non-fatal
cardiovascular events was applied, encompassing a wider range of non-fatal
ischemic heart diseases (I21–I24) and stroke (I60–I64).
Results
Characteristics of the study population and control group building
The study population consists of 13,101 matched pairs, which corresponds to
26,202 individuals. Two participants could not be matched as no control subject
with an identical propensity score was available (Figure 1). As we accepted all
subjects who so far had never been enrolled in ‘KardioPro’ at the point of
matching, 604 control subjects became subsequent participants and were censored
at this point in time. In total, 134 control subjects and 153 participants were lost
to follow-up as a result of leaving the SBK. Characteristics of the study population
are presented in Table 1.
Before matching, in 23 of 357 comparisons (one comparison per variable per
year, i.e. 119 variables times 3 years), the standardized difference exceeded 10%.
Thus, the corresponding variables were not well balanced between the
intervention and control groups. After matching, only four comparisons exceeded
this value. The area under the receiver operating characteristic curve, a measure to
quantify how well the propensity score distinguishes between ‘KardioPro’
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participants and control subjects, was 0.771 for the matching year 2006, 0.784 for
2007 and 0.797 for 2008.
Time-to-event analysis
The Cox regression for the primary endpoint ‘all-cause mortality, acute MI and
ischemic stroke’ showed a risk reduction of 23.5% (95% confidence interval (CI)
13.0–32.7%, absolute risk reduction 0.29%). For the secondary endpoint ‘all-cause
mortality’, the risk reduction was 41.7% (95% CI 30.2–51.2%). Within the follow-
up period, a reduction of 31 deaths per 10,000 ‘KardioPro’ participants per year
was observed (i.e. absolute risk reduction 0.31%). Secondary analysis for the
combined endpoint of ‘non-fatal acute MI or non-fatal ischemic stroke’ did not
reveal a significant risk reduction (hazard ratio 0.964, 95% CI 0.811–1.148%,
absolute risk reduction 0.03%) (Table 2). The Kaplan–Meier curves illustrated the
cumulative probability of an event regarding the different endpoints (Figures 2–
4). Please note the rapid decrease in subjects at risk after 3 years, as enrolment
took place continuously and the regions where ‘KardioPro’ was offered were
extended over time.
Further analyses
The frequency of elective PCI and CABG was significantly increased for
‘KardioPro’ participants compared with control subjects (PCI: 409 vs. 255,
p,0.0001; CABG: 96 vs. 67, p50.028; for details, see Table 3). There were no
significant differences in the changes in disease statuses of participants and control
Figure 1. Participant flow diagram.
doi:10.1371/journal.pone.0114720.g001
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Table 2. Results of time-to-event analysis.
Endpoint
Time under observation
(person years) Number of events* 3.5-year survival
Hazard ratio (95%
CI) p-value






44,101 42,270 444 550 96.6% 95.6% 0.765 (0.673–0.870) ,0.0001




44,101 42,270 264 266 97.9% 97.9% 0.965 (0.811–1.148) 0.69
CI: confidence interval.
*As the time under observation of fatal and non-fatal events differs, the number of deaths and the number of non-fatal events do not sum to the number of
events of the combined endpoint.
doi:10.1371/journal.pone.0114720.t002
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subjects from the year of matching to the year of enrolment (2006–2007,
p50.5038; 2007–2008, p50.3725).
Sensitivity analysis
The sensitivity analyses showed similar results to the primary analysis regarding
the combined endpoint of ‘all-cause mortality, acute MI and ischemic stroke’
(simultaneous censoring: 23.5% (95% CI 13.0–32.7%), adjustment: 26.3% (95%
CI 14.0–36.9%), modified matching algorithm: 20.2% (95% CI 9.4–29.7%) and
Mahalanobis distance matching: 23.4% (95% CI 12.9–32.7%)). With regard to the
additional sensitivity analyses, the results of the primary outcome also did not
deviate severely from the primary analysis, when excluding people with severe
illnesses from the analysis. Likewise, including a wider range of cardiovascular
events in the endpoint yielded a small non-significant risk reduction, which is
comparable to the results of the combined endpoint ‘non-fatal acute MI or non-
fatal ischemic stroke’. The results of these additional sensitivity analyses are
reported in the supplementary material (Table S2).
Figure 3. Kaplan–Meier curves with point-wise 95% confidence bands for the endpoint ‘all-cause mortality’.
doi:10.1371/journal.pone.0114720.g003
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Discussion
In this study, the effectiveness of ‘KardioPro’ was evaluated based on routine data.
There was a significant risk reduction regarding the primary endpoint of ‘all-cause
mortality, acute MI and ischemic stroke’ and also regarding the secondary
endpoint of ‘all-cause mortality’. However, the endpoint ‘non-fatal acute MI or
non-fatal ischemic stroke’ was associated with a small non-significant risk
reduction.
Figure 4. Kaplan–Meier curves with point-wise 95% confidence bands for the endpoint ‘non-fatal acute myocardial infarction and non-fatal
ischemic stroke’.
doi:10.1371/journal.pone.0114720.g004
Table 3. Effect of ‘KardioPro’ on elective* interventions (McNemar tests).
Percutaneous coronary intervention (PCI) ‘KardioPro’ participants
PCI ‘no’ PCI ‘yes’ p-value
Control group PCI ‘no’ 12,447 399
PCI ‘yes’ 245 10 ,0.0001
Coronary artery bypass grafting (CABG) ‘KardioPro’ participants
CABG ‘no’ CABG ‘yes’
Control group CABG ‘no’ 12,938 96
CABG ‘yes’ 67 0 0.028
*Elective: interventions that did not take place on the day of a myocardial infarction.
doi:10.1371/journal.pone.0114720.t003
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Such a discrepancy in results between endpoints with and without fatal events
in the context of cardiovascular prevention programmes has been observed
previously [33]. To discover the reasons for this phenomenon, we analysed how
possible types of bias may affect the results. A main source of potential bias is
voluntary enrolment into ‘KardioPro’ without randomization. If the members of
the intervention group were healthier than the control subjects (‘healthy cohort
bias’), the mortality in the intervention group could be lower, and this effect could
be incorrectly attributed to ‘KardioPro’. We aimed to minimize this bias by
building an appropriate control group via propensity score matching in which we
included comorbidity in the year prior to enrolment as an independent variable.
Although all-cause mortality was lower, we did not observe fewer vascular events
in KardioPro participants, which would be expected in the case of ‘healthy cohort
bias’. Although we cannot fully rule out a ‘healthy cohort bias’, we could rule out
by our analyses major manifestations of this bias.
Another potential problem is ‘ascertainment bias’: individuals with health-
conscious behaviour have been observed to volunteer for preventive measures
[34]. In this case, participants would have greater medical attention and events
would be prevented independently of the participation in ‘KardioPro’. In such a
group, there should also be early detection of other severe illnesses, and the
number of newly diagnosed comorbidities per year should be higher too.
Therefore, we analysed whether the numbers of newly documented comorbidities
in the first year after enrolment differed between the intervention and control
groups. No difference was identified, which does not support the notion of
ascertainment bias.
Healthy cohort bias as well as ascertainment bias could be reasons for the
observed protective effect of ‘KardioPro’ within the first year of participation. As
prevention programmes often become fully effective after a delay, this can make a
bias appear possible. Yet, besides risk factor elimination, ‘KardioPro’ was aimed at
the detection of undiagnosed CHD. Therefore, it is conceivable that in some cases
impending events had been avoided. The small number of prevented deaths
within the first year of participation in ‘KardioPro’ is thus not unlikely, and is not
necessarily a result of selection bias.
Despite the results of our analyses and the mentioned aspects, it is not possible
to exclude the possibility that bias was still present.
A further source of bias could be misclassification of events within routine data
[35]. To reduce bias from incorrectly classifying previous events as newly
occurring events, only the first event was counted. Furthermore, ‘hard’ and
relevant endpoints of mortality from all causes, acute MI and ischemic stroke were
included where it was more unlikely to miss or misdiagnose these events [20]. The
events MI and stroke were based on hospital diagnosis data, which allowed a quite
reliable estimation of non-fatal events. However, the number of hospital-
documented cardiovascular events was only significantly reduced when combined
with all-cause mortality. As the reason for out-of-hospital mortality has not been
documented within routine data, it was not possible to focus directly on
cardiovascular mortality. This necessitated including all-cause mortality in the
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primary endpoint. A systematic bias in all-cause mortality is unlikely, but bias for
non-fatal events cannot be excluded. For example, ‘KardioPro’ could have yielded
greater attention to cardiovascular events, and thus a higher probability of
diagnosis. This would have underestimated the protective effect of ‘KardioPro’.
The results can be summarized as follows: per year per 10,000 ‘KardioPro’
participants, there was a reduction of 32 deaths but, regarding the combined
endpoint ‘death, acute MI and ischemic stroke’, there was a reduction of only 27
cases. This can be explained by five additional cases of non-fatal cardiovascular
events. However, this secondary endpoint was not significant.
One possible interpretation of these results would be a reduction in
cardiovascular events (both fatal and non-fatal) combined with a shift from fatal
to non-fatal events. The increase in elective events in the intervention group
supports the hypothesis that the prevention programme leads to early detection
and optimized treatment, which could be an explanatory factor in the reduction
in mortality. Although no evidence could be found to contradict this possibility,
data to further support it were lacking, especially as cause of death is not
documented in the claims data analysed, inhibiting differentiated evaluation of
fatal outcomes.
The propensity score matching appeared to be suitable for control group
building. After matching, the intervention and control groups appeared to be well
balanced. A limitation of ‘KardioPro’ is that, for propensity score matching, not
all potentially relevant variables were covered by the routine data. For example,
smoking behaviour or blood pressure are known to affect cardiovascular
incidence, but cannot be found in sickness fund routine data. This may potentially
lead to bias [36]. Another potentially relevant variable that was not available for
propensity score matching was participation in disease management programmes.
Moreover, socioeconomic status, which could have an influence on health, is only
unsatisfactorily documented. Although the propensity score matching included
variables that are likely to be associated with socioeconomic status, such as place
of residence, type of insurance (e.g. compulsory, voluntary, retirement and
unemployment) and status of reduced earning capacity, we cannot fully rule out
the possibility that ‘KardioPro’ participants, on average, had higher socio-
economic status.
Furthermore, it has not been possible to assign the effectiveness of ‘KardioPro’
to the single components of the multifactorial prevention programme. This would
have been associated with a considerable amount of bias resulting from control
group building, as the access to single components has already been affected by
risk stratification.
Regarding sensitivity analysis, it was surprising that excluding future
‘KardioPro’ participants from the pool for the control group yielded a lowering of
the effect of ‘KardioPro’. However, in the absence of bias, this sensitivity analysis
could have changed in either direction, just by chance. As all matched partners
were changed within this sensitivity analysis, it is hard to judge whether the
change is significant. A potential explanation would be an increasing effectiveness
of ‘KardioPro’ over time. However, we could not confirm this empirically, as the
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Schoenfeld residuals of the Cox regression models did not contradict the
proportional hazards assumption.
The strengths of this study are the large sample size of 26,202 individuals,
including male and female study participants. Furthermore, these analyses
represent an evaluation of ‘KardioPro’ as a whole under real-world conditions of
the total target population by relinquishing strict exclusion criteria apart from age.
With a maximum follow-up of 5 years and a mean observation time of 3.3 years,
the follow-up time was comparatively long [37]. Furthermore, multiple sensitivity
analyses have been conducted to test the robustness of the results. Besides this
effectiveness analysis, analyses of costs associated with ‘KardioPro’ are anticipated.
Conclusion
Participating in ‘KardioPro’, a structured programme for CHD diagnosis and
therapy that included risk-dependent regular check-ups regarding the reduction
of coronary risk, was associated with reduced all-cause mortality. Given the
comprehensive control of influencing variables in this study, it seems likely that
fatal cardiovascular events may also have been reduced by this programme. The
non-significant result regarding the endpoint ‘non-fatal acute MI or non-fatal
ischemic stroke’ might be explained by a shift from fatal to non-fatal events
through ‘KardioPro’. Even though propensity score matching has been
performed, the evaluation study still has an observational design, which we
consider to be its major limitation. When planning future prevention
programmes, we therefore recommend incorporating a randomization strategy.
For example, cluster randomization might be suitable to minimize bias.
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